Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia
Hemab Therapeutics, a late-stage clinical biotechnology company headquartered in Cambridge, Massachusetts, and Copenhagen, Denmark, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sutacimig, a subcutaneously administered bispecific antibody, for the prevention of bleeding episodes in patients with Glanzmann thrombasthenia (GT). Sutacimig, formerly designated HMB-001, binds and stabilizes endogenous Factor VIIa with one antibody arm while binding TLT-1 on activated platelets with the other, facilitating hemostatic plug formation. Hemab Therapeutics is a privately held company with no public stock ticker.
Procedural Benefits of the Designation
BTD provides Hemab Therapeutics with intensive FDA guidance on drug development, organizational commitment from senior FDA managers, and eligibility for rolling review, which permits submission of completed sections of a marketing application before the entire filing is ready. These procedural mechanisms are designed to compress development and review timelines for drugs targeting serious or life-threatening conditions where preliminary clinical evidence indicates potential for substantial improvement over existing therapies.
Clinical Development of Sutacimig for Glanzmann Thrombasthenia Treatment
Sutacimig was originated and developed in-house by Hemab Therapeutics, founded in 2019 from academic research in Scandinavian coagulation biology. The molecule was not acquired or in-licensed from an external entity. The BTD was granted on the basis of data from the completed Phase II multiple ascending dose portion of Hemab's Phase I/II clinical trial (NCT06211634). In that study, the weekly dosing group achieved an estimated 87% reduction in annualized treated bleeding rate, with consistent reductions observed across bleed types, locations, and dosing cohorts. All tested doses produced over a 50% reduction in treated bleeding events. No major safety signals were reported in public disclosures from the Phase II portion. Hemab has stated plans to advance sutacimig into a pivotal Phase III study.
Prior to this BTD, sutacimig had already received Fast Track Designation and Orphan Drug Designation from the FDA, orphan medicinal product designation in the European Union, and Innovative Licensing and Access Pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency.
Research Context
GT is a rare, inherited platelet disorder caused by deficiency or dysfunction of the glycoprotein IIb/IIIa complex, resulting in impaired platelet aggregation and recurrent, sometimes life-threatening bleeding. Data from the international GT360 natural history study reported that 88% of 117 participants experienced at least one bleed in the prior week, and 65% required a bleed-related hospital visit within six months. Over 80% had missed work or school, and more than 50% faced restrictions on social activities and travel.